Peter Sever

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter et al. · The Lancet · 2003 · 3.8K citations

Medicine, Cardiology, Pharmacotherapy +14

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Björn Dahlöf, Peter Sever, Neil R Poulter et al. · The Lancet · 2005 · 2.9K citations

Medicine, Cardiology, Pharmacology +10

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

Peter M. Rothwell, Sally C. Howard, Eamon Dolan et al. · The Lancet · 2010 · 1.8K citations

Medicine, Cardiology, Internal Medicine +14

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Bryan Williams, Thomas M. MacDonald, S. V. Morant et al. · The Lancet · 2015 · 1.2K citations · Full text

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +16

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 948 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17